5-Amino-1MQ

Small-molecule NNMT inhibitor studied in metabolic and obesity research.

Evidence: Preclinical / Animal Function: Metabolic Class: Small-molecule analog

Explore calculators for this compound

Use the Peptide Research Tools to experiment with reconstitution-style scenarios, mg/kg ranges and simplified half-life curves for 5-Amino-1MQ. All values are placeholders and must be aligned with your own research protocol.

Open 5-Amino-1MQ in calculators →

Research focus & potential applications

5-Amino-1MQ is investigated as a selective inhibitor of nicotinamide N-methyltransferase (NNMT) in adipose and metabolic tissues. Preclinical work explores its role in modulating fat mass, NAD+ flux and insulin sensitivity in models of obesity and metabolic dysfunction.

Research areas & putative benefits

Summarizing how 5-Amino-1MQ is being explored in the literature – framed as research questions, not clinical claims.

Reduction of white adipose tissue mass and adipocyte size in diet-induced obese animal models without changes in food intake.
Restoration of intracellular NAD+ levels and modulation of SAM / 1-MNA flux through NNMT inhibition in adipocytes.
Improvement of insulin sensitivity and glucose tolerance in models of metabolic syndrome and type 2 diabetes.
Broad effects on cellular energy expenditure and mitochondrial function in metabolically compromised tissues.

Mechanism stack

High-level pathways implicated when NNMT is inhibited by 5-Amino-1MQ in preclinical models.

Primary target

NNMT inhibition

Selectively inhibits nicotinamide N-methyltransferase, reducing conversion of nicotinamide to 1-MNA and altering methylation flux in adipocytes.

NAD+ salvage

NAD+ preservation

By limiting nicotinamide methylation, more nicotinamide may remain available for recycling into NAD+, supporting cellular redox and sirtuin activity.

Energy metabolism

Fat cell energy expenditure

Preclinical work suggests increased energy expenditure and reduced lipogenesis in white adipose tissue, leading to smaller fat cells and lower fat mass.

Metabolic health

Insulin sensitivity & lipids

Animal studies report improved insulin sensitivity and changes in plasma lipids alongside reduced adiposity, proposing NNMT as a metabolic target.

Evidence snapshot

Representative findings from preclinical and early translational work on 5-Amino-1MQ and related NNMT inhibition.

Model / context	Observation	Notes
Differentiated adipocytes (in vitro) Cellular	NNMT inhibition reduced 1-MNA levels, increased NAD+ and SAM, and suppressed lipogenesis in fat cells.	Mechanistic demonstration that NNMT controls metabolic flux in adipocytes.
Diet-induced obese mice Animal (obesity model)	Treatment with an NNMT inhibitor decreased body weight and white adipose mass, reduced adipocyte size, and lowered plasma cholesterol, without affecting food intake.	Suggests weight and fat mass changes are driven by altered metabolism rather than appetite suppression.
Metabolic syndrome / T2D models Preclinical metabolic	Reports of improved insulin sensitivity and glucose handling when NNMT activity is reduced in adipose tissue.	Positions NNMT as a potential target for insulin resistance and related metabolic dysfunction.
Translational outlook Research trajectory	Proposed as a candidate for further study in obesity, type 2 diabetes and age-related metabolic decline.	As of now, large-scale human outcome data remain limited or absent.

Risk frame & unknowns

Key limitations and open questions highlighted by current research.

Important research caveats

Evidence base is predominantly preclinical (cell and animal data); robust human safety and efficacy data are not yet established.
Long-term effects of chronic NNMT inhibition on global methylation, NAD+ metabolism and off-target tissues remain incompletely characterized.
No approved medical indication; use is confined to research and experimental contexts.
Metabolic manipulation may have context-dependent effects that differ between lean, obese, young and older organisms.

This page summarizes mechanistic and preclinical findings for scientific orientation. It does not provide medical advice, treatment guidance or dosing recommendations.